Digital Pathology: Take Your Next Step On the Path to Implementation
Digital pathology can help overcome time, productivity, and quality constraints often associated with manual microscopy, by enabling you to work in the digital environment. Additional benefits of implementing digital pathology into your research projects are highlighted below.
Why Go Digital?
Digital pathology is the practice of converting microscopic glass slides into digital slides that can be viewed, managed, and analyzed on a computer screen or mobile device. Digital pathology is being readily adopted by research organizations to enhance biomarker and drug discovery. Here are the top reasons to implement digital pathology.
Improve Quality & Productivity
Reduced errors:
Helps prevent breaking of precious slides due to excess handling, and need to ship to distant laboratories. Misidentification may also be reduced by barcoding of slides.
More innovation:
Big data provides more research outputs for complex research questions. Allows research groups to collaborate at broader locations. Provides tools for teaching and training at different locations.
Improved analysis:
Improve accuracy in tissue analysis by removing the subjectivity and inter-/ intra-observer variability inherent in manual review, as well as providing a comprehensive, quantitative analysis.
Improved workflow:
Central storage and data management systems for digitized slides enables international collaboration, a more streamlined workflow, and for more flexible work schedules.
A new way to view:
Team annotation of slides. Measure multiple areas of interest with multiple people annotating. Get a dashboard view of all annotations for analysis. Simultaneous view of slides from the same study.
Reduced turnaround time:
Enables immediate access to archive digital slides compared to searching in physical repositories. Also reduces time in retrieving, matching and organizing data within a study.
For research use only. Not for use in diagnostic procedures
About the presenter
Rhian is a Scientist from Swansea University in Medical and Healthcare Studies and was featured in several collaborative publications. Rhian’s research-based background focused on tissue-based pathology in Multiple Sclerosis, primarily using immunohistochemical analysis and in vitro molecular techniques. She spent a short period conducting routine PCR testing for COVID-19 at the end of 2020.
Related Content
Leica Biosystems content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.
For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.